1. Introduction {#S5}
===============

Those with multimorbidity are an emerging patient population that is challenging health care systems worldwide. For example, almost half of all US adults live with one chronic illness \[[@R1]\] and multimorbidity is increasing as the population ages \[[@R2]\]. Accordingly, recent estimates suggest that two-thirds of US Medicare beneficiaries (close to 21 million patients) have two or more chronic conditions and more than one-third have four or more \[[@R3],[@R4]\]. Similarly, in Australia and Europe, a quarter of the population has multimorbidity, with prevalence and complexity increasing with age: 83%, 58% and 33% of patients aged 75 years or older have at least two, three or four concurrent conditions, respectively, requiring active management \[[@R5],[@R6]\]. Unsurprisingly, multimorbidity is not a benign phenomenon. The risk of hospitalisation, re-hospitalisation, and death rise as the number of chronic conditions increases \[[@R7]\].

Multimorbidity is common in patients with heart failure (HF), increasing their risk for poor health outcomes. Lone HF is rare and is exceedingly rare in the predominant HF patient population aged 75 years and older \[[@R8]\]. In the US, approximately 40% of Medicare beneficiaries with HF have \>5 non-cardiac conditions and this group accounts for \>80% of the total inpatient HF-related hospital days in the US \[[@R9]\]. Annual total costs for HF are expected to more than double between 2012 and 2030 (\$31 billion to \$70 billion USD) \[[@R10]\] making HF the foremost contributor to Medicare expenditures \[[@R11]\]. The majority (61%) of hospital readmissions are attributable to multimorbidity \[[@R12]\], and occur within 15-days of discharge \[[@R13]\]. About half of all hospitalisations in HF patients are thought to be preventable \[[@R9]\]. This is particularly problematic in those with HF and preserved ejection fraction, for whom multimorbidity is the major driver of hospitalisations. To date, authors of expert guidelines have struggled to address the issue of multimorbidity in HF and articulate clear pathways to optimise health outcomes. Not surprisingly, however, there has been increasing interest in providing clinicians and health care teams with more guidance to improve the management of HF in the context of multimorbidity \[[@R14]\].

2. Aims {#S6}
=======

We recognise the complex clinical challenges inherent to managing HF in the setting of multimorbidity and the limitations of practice guidelines in providing a comprehensive overview of the applicability of treatment options. Thus, the specific aims of this position paper (from an international, multidisciplinary panel of health professionals with an ongoing interest and expertise in HF management) are two-fold: To provide a comprehensive overview of the current literature focussing on the most common conditions requiring concurrent treatment and management in patients with HF.To articulate a practical framework for establishing a systematic response to this increasingly common clinical phenomenon that has the potential to improve health outcomes.

We explicitly recognise that the practical steps outlined in this document are yet to be proven in terms of improved health outcomes (indeed they form the basis for a proposed, international, multicentre trial). However, we propose that these steps be used (in part or in their entirety) to inform and complement contemporary guidelines to improve health outcomes in those affected by HF and multimorbidity, regardless of the health care system in which they are managed.

3. Literature review {#S7}
====================

We began by surveying the literature, noting a contemporary study of multimorbidity in the HF patient population \[[@R15],[@R16]\]; we identified the ten most prevalent concurrent conditions in HF (other than hypertension and ischaemic heart disease) requiring concurrent management. The ten most prevalent conditions (other coronary disease and hypertension) identified in the literature were anaemia, sleep disordered breathing, respiratory disease, Type 2 diabetes, depression, renal impairment, cognitive impairment, musculoskeletal disorders, arrhythmias, and thyroid disease. This list was then validated in two large patient cohorts (\>1000 patients) in Australia and the USA via purposeful profiling (comprising detailed psychosocial and clinical phenotyping) of typically older patients with HF at the time of hospital discharge. Whilst we acknowledge this may not represent the definitive "top ten" list of concurrent conditions in HF (indeed we considered a number of other potential conditions of interest) in all settings, we largely focus on our validated list. These conditions are often closely linked, occur concomitantly, and represent natural targets for better management from a multimorbidity perspective due to the typical clinical "conundrum" they represent --- see [Fig. 1](#F1){ref-type="fig"}: A conundrum of multimorbidity in HF (reproduced with permission) \[[@R15]\]. As depicted in [Fig. 1](#F1){ref-type="fig"}, the patterns of interaction in multimorbidity present an opportunity to prospectively manage predictable gaps in patient care, such as polypharmacy, care coordination, and communication among multidisciplinary providers.

Focussing on these ten pre-specified conditions, we then searched the literature (using the specific search terms outlined in [Table 1](#T2){ref-type="table"}) to identify publications focused on the management of these conditions in the setting of HF. Specifically, the search was performed using Medline and was limited to reports published during the period 2005 to 2015, in order to capture the most up-to-date literature. Ten individual searches were conducted in which the specific co-morbidity of interest, along with HF, and their combined management or treatment was entered into Medline. This yielded a total of 3573 citations, which were then reviewed for relevancy --- see [Table 1](#T2){ref-type="table"}. The full text articles were reviewed and a tabulated summary of extracted information from 194 papers is provided in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.

The literature reviewed using this search strategy and subsequent data extraction (noting the often fragmented approach to examining multimorbid conditions in HF) was contextualised according to the authors' own experiences in managing large numbers of older patients (i.e. those aged 75 years or more) with HF and multimorbidity. A pragmatic clinical framework, ARISE-HF, (comprising a series of five key steps --- see text box below) to frame clinical practice, research, and future health policy was initially drafted by SS and BR and subsequently circulated for review, revision and approval by the group.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ARISE-HF
  A = Acknowledge multimorbidity as a clinical syndrome that is associated with poor health outcomes
  R = Routinely profile (using a standardised protocol - adapted to the local health care system) all patients hospitalised with HF to determine the extent of concurrent multimorbidity
  I = Identify individualised priorities and person-centred goals based on the extent and nature of multimorbidity
  S = Support individualised, home-based, multidisciplinary, case management to supplement standard HF management
  E =Evaluate health outcomes well beyond acute hospitalisation and encompass all-cause events
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The section below expands upon the ARISE-HF framework and how it might be applied on a systematic basis.

4. A step-wise approach to improve health outcomes (ARISE-HF) {#S8}
=============================================================

4.1. Step 1: Acknowledge multimorbidity as a clinical syndrome associated with poor health outcomes {#S9}
---------------------------------------------------------------------------------------------------

As previously noted by Tinneti and colleagues \[[@R17]\], multimorbidity in HF has emerged as a clinical syndrome associated with poor health outcomes. Based on our review of the literature (see below), it is reasonable to classify HF with concomitant multimorbidity as a distinct clinical syndrome in order to provoke a more systematic response from the health care system. For example, it is of particular concern that HF patients with a high burden of multimorbidity living in low-income areas are at increased risk for all-cause re-hospitalisation, suggesting that illness burden may influence the association between income and outcomes in these patients \[[@R18]\]. In contrast to an increasing recognition that specific clusters of conditions are associated with extended length of hospital stay, elevated cost, and increased risk of mortality \[[@R19]\], the current literature is largely fragmented, focussing on common clinical dyads (e.g. HF and diabetes) and framing clinical management in isolation from other complicating factors (e.g. renal dysfunction). [Supplementary Table 1](#SD1){ref-type="supplementary-material"} summarises key clinical issues for each condition of interest.

4.2. Step 2: Routinely profile (using a standardised protocol) patients with HF to determine the extent of concurrent multimorbidity {#S10}
------------------------------------------------------------------------------------------------------------------------------------

A logical extension to recognising multimorbidity in HF as a clinical syndrome requiring a coordinated clinical response is to identify which patients (particularly those at high risk of related poor health outcomes) are affected by what condition. As such, we recommend all older patients admitted to hospital with HF should be systematically profiled for multimorbidity in order to optimise care. At minimum, this would include the ten common conditions identified that complicate HF management (other than routinely diagnosed and managed coronary artery disease and hypertension) with consideration of other potential conditions according to the patients clinical profile. In the presence of multiple admissions/clinical instability, it would be reasonable to review the extent and progression of multimorbidity on a regular basis. Findings should be noted in the clinical records and included as part of any communication with the patient's wider health care team. Advanced electronic health records (EHR) and informatics would facilitate both the identification and tracking of such individuals. However, EHR capacity is highly variable across different health systems. It is also important to note that any protocol for managing patient's with HF and multimorbidity will likely rely on a component of "routine" profiling (e.g. review of prior records and standard review of electronic systems) as well as an active component of profiling (e.g., to determine cognitive function). Although profiling focusses on hospitalised individuals, there is a clear need to consider when it is best and most reliable to perform profiling; ideally when the individual is clinically stable and, in some cases, post hospital discharge. The latter in particular requires clear lines of communication with the primary health care team. [Table 2](#T3){ref-type="table"} summarises the definitions and methods that might be routinely applied to identify ten common comorbid conditions in HF (i.e. those conditions of particular interest to this position paper).

4.3. Step 3: Identify individualised priorities and person-centred goals based on the extent and nature of multimorbidity {#S11}
-------------------------------------------------------------------------------------------------------------------------

As shown in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}, there are potentially many competing priorities arising from multimorbidity in HF that are not easily addressed in a generic manner --- hence the historical difficulty for guideline committees to provide specific recommendations in the setting of marginal benefit-risk ratios. For example, there has been a reluctance to prescribe high doses of neurohormonal/vasodilator therapy in the setting of frailty and high risk of falls and/or evidence of progressive renal dysfunction despite the potential benefits \[[@R20],[@R21]\]. On this basis, we suggest a structured approach that considers the nature and severity of multimorbidity, defines an individualised list of clinical priorities and identifies the need for specialist consultation when appropriate. Critically, as part of a patient-centred approach, patient preferences and goals regarding their own health \[[@R22]\], as well as conflicting and contraindicated treatment options should play a prominent role in the decision points of the algorithm. This requires a truly multidisciplinary, team-based approach to management \[[@R23]\] that provides the patient and their caregivers with the knowledge to foster better care and to provide advice on their options pertaining to their treatment and management. Whilst we have suggested a clear focus on the hospitalised patient (with the opportunity to complete most if not all components of screening for multimorbidity), it is clear that subsequent management will be applied within the community/out-patient setting. A suitably qualified health professional (such as an experienced nurse with relevant qualifications) has the capacity to generate realistic and achievable care/action plans when --- a) consulting and assessing patients in their home and then b) consulting with the wider health care team to determine what can be done to meet the patient's needs \[[@R24]--[@R26]\].

4.4. Step 4: Support individualised, home-based, multidisciplinary, case management to supplement standard HF management {#S12}
------------------------------------------------------------------------------------------------------------------------

As recently articulated in the AHA/ACC/HHS Strategies to Enhance Application of Clinical Practice Guidelines in Patients with Cardiovascular Disease and Comorbid Conditions \[[@R27]\], there is a compelling imperative to adjust management strategies in the setting of multimorbidity, and standard HF management is no exception. Beyond recognising and characterising multimorbidity (see recommendations 1--3), strategic plans that are robust (i.e., can be applied in different health care systems with variable personnel, capacity and resources), flexible, feasible, cost-effective and focused on addressing each problem in the broader context need to be formulated.

### 4.4.1. Management options {#S13}

Disease management has demonstrated benefit for improving clinical outcomes. In the last two decades, a variety of robust HF disease management approaches have been developed and tested, aimed at improving HF outcomes and reducing hospitalisations \[[@R26],[@R28]--[@R31]\]. Numerous meta-analyses have documented the effectiveness of disease management programmes for HF \[[@R32]--[@R40]\]. However, implementation of these programmes in clinical practice is highly variable. This is reflected in a recent study confirming wide variation in the care provided to HF patients after discharge from the hospital \[[@R41]\]. A pooled analysis of ten HF disease management RCTs highlighted that the essential components of these programmes in reducing the number and length of hospital admissions were multidisciplinary, team-based care that included in-person communication between case managers, physicians and patients \[[@R42]\].

It is notable that much of the evidence-base supporting HF disease management programmes, for both historical and practical reasons, has been primarily focused on relatively less complex cases, and thus is less applicable to the population with HF and multimorbidity. Yet, epidemiological data show that patients hospitalised with HF are becoming increasingly older (with associated multimorbidity rising at the same time) \[[@R43]--[@R45]\]. Accordingly, more contemporary clinical trials of HF management are dealing with older and more complex cases \[[@R46], [@R47]\]; particularly when compared to earlier trials focussing on managing HF patients on an outpatient/ambulatory basis (the predominant model of care in many parts of the world \[[@R48]\]. Unfortunately, therefore, the relevance of previously effective management programmes in HF is likely to be eroded by an increasing proportion of patients with HF and multimorbidity with more challenging clinical priorities. Indeed, this may explain the neutral results of trials of more HF-centric interventions such as the COACH Study \[[@R49]\] and those applying remote monitoring techniques \[[@R50]\]. In comparison, positive results of home-based management when compared to clinic-based treatment in the WHICH? Trial \[[@R25]\] suggests a promising approach for those with HF and multimorbidity. To our knowledge, however, there are no definitive approaches to improve typically poor health outcomes that extend beyond standard HF management models of care.

The inherent complexity of managing multiple comorbid conditions is exacerbated by issues such as frailty, social isolation, impaired cognition and limited income that frequently negatively impact on sufferers of HF, who are typically elderly \[[@R51]--[@R53]\]. Although practical and disease-related issues are often closely interrelated \[[@R16],[@R54]--[@R56]\], complexity is often overlooked, adversely affecting quality of life, hospital admission risk and survival \[[@R57]--[@R59]\]. Recent research reveals that it is these very complex, multimorbid or high-risk patients who stand to benefit most from home-based patient-centred management programmes \[[@R60]\]. From a health-cost perspective, the home-based approach to patient-centred management has been shown to be more both clinically beneficial (reduced hospital stay and prolonged survival) and cost-effective when compared to an equivalent specialist HF clinic in the head-to-head WHICH? Trial. Notably this trial specifically targeted older patients with HF and multimorbidity \[[@R61]\]. Taken together, these findings support the need for a paradigm shift --- away from disease management, which by definition targets a specific primary disease (e.g. HF), to a more holistic approach, which considers each condition in the broader context of competing morbidities and seeks to design care in a way that optimises patient-centred outcomes (i.e., patient-centred care).

### 4.4.2. Coordinating care in the setting of multimorbidity in HF {#S14}

Interventions addressing multimorbidity and clinical complexity in this population have the potential to reduce hospitalisations and prolong survival beyond that achieved by traditional disease management and transitional care programmes. The latter targets poor communication and poorly coordinated transitions at hospital discharge that contribute to negative health outcomes and increases the financial burden on the healthcare system (i.e., adverse events and increased hospitalisations) \[[@R62]\]. Transitional care is effective in older adults with HF who require complex care \[[@R63]\]. However, transitional care typically continues for at most 3-months after hospital discharge, which risks readmission if self-care is not mastered and/or comorbid conditions are not stabilised during that period. Although interventions for specific disease combinations have been tested (e.g., HF and diabetes) \[[@R64]--[@R67]\], clinical guidelines integrating the care of multiple conditions are rare. \[[@R68]\]. Other approaches such as interdisciplinary primary care \[[@R69]\] and interdisciplinary teams for nursing home residents \[[@R70]\] are in the early phases of testing. Two promising interventions for multimorbidity are patient-centred medical homes \[[@R71]\] and Guided Care \[[@R72]--[@R74]\]; both of which have the potential to overcome the challenge of home-bound individuals accessing community resources \[[@R75]\]. Likewise, the effectiveness of physician house call programmes \[[@R76]\], as well home-support with a more diverse team such as the CAPABLE team (comprising a nurse, an occupational therapist and a handyman) are being evaluated \[[@R77],[@R78]\].

### 4.4.3. An emphasis on self-care {#S15}

Self-care important in any health condition, is particularly crucial for patients with complex illnesses and comorbidity. The seminal work in defining self-care in adults with chronic illness has been undertaken by Riegel and colleagues \[[@R79]--[@R81]\], who have conducted numerous studies aimed at understanding \[[@R82]--[@R86]\] and strengthening the ability of patients to perform self-care activities including adherence to medications and diet, as well as the detection and management of symptoms \[[@R87]--[@R89]\]. Encouragingly, a recent pilot study demonstrated that in a predominantly minority HF sample with significant multimorbidity, a tailored home-based intervention using motivational interviewing and skill-based education \[[@R87],[@R89]\] achieved a statistically significant and clinically meaningful improvement in self-care that exceeded that of standard care \[[@R90],[@R91]\]. Furthermore, hospitalisations unrelated to HF were less frequent in the group receiving the intervention \[[@R92]\]. Overall, there is good evidence to suggest that enhanced self-care can decrease symptom severity, improve health related quality of life (HRQoL), delay acute decompensation, and prevent hospitalisation in HF patients \[[@R93]--[@R95]\].

### 4.4.4. A carer-centred approach {#S16}

Given that self-care may be particularly challenging for those HF patients with comorbid conditions such cognitive impairment \[[@R96]\], it is vital that the role of the family and other caregivers be recognised and supported. A recent systematic narrative review revealed that despite the pivotal role played by caregivers in the care of HF patients, their needs have not been clearly understood \[[@R97]\]. Three major areas of need identified were, 1) psychosocial support to maintain a sense of normalcy, 2) support with daily living, and 3) support navigating the healthcare system. Although health professionals agree that patient and caregiver uncertainty and unmet needs are major problems, they feel lacking in knowledge, opportunities, or have adequate support to improve the situation \[[@R98]\]. In order to improve outcomes for both caregivers and HF patients, it seems clear that an individualised, person and family-centred approach is required and must address issues arising both from HF and from multimorbidity. In addition, it is vital for future research to focus on how to optimally support and assist caregivers.

### 4.4.5. Applying case management in multimorbidity {#S17}

Case management is a collaborative process used to assess, plan, implement, coordinate, monitor, and evaluate the services required to meet a patient's health and human service needs \[[@R99]\]. The case management process is characterised by communication, resource management, and advocacy with a focus on promoting quality and cost-effective care. A key component of case management, as with other successful disease management strategies, is a post-discharge home visit to chronically ill, older adults who have complex social and environmental issues (e.g., social isolation, financial stress) that are rarely recognised and addressed in routine clinical care \[[@R57]--[@R59]\]. In addition to shifting the locus of control to the patient and assessing any residual signs of clinical instability, a post-discharge home visit permits a physical walk-through of the home with the patient, noting any environmental issues that would compromise safety, most notably entry sites and steps, bathroom areas and flooring (e.g. loose rugs that may require attention for those with physical frailty). At the same time, this visit allows the case manager to assess and support self-care abilities in a naturalistic environment; permitting them to tailor interventions to address the individual characteristics of the recipient \[[@R100]\], and focussing on skill rather than simply knowledge \[[@R87],[@R89]\]. Additionally, including physiotherapy-based treatments may be beneficial as it has been recently shown that physiotherapy assists in falls prevention and reducing functional deficits in those with cardiovascular disease \[[@R101]\]. Specifically, aerobic or resistance training can assist to improve physical performance and HRQoL, and may increase the probability of older adults remaining independent \[[@R101],[@R102]\], with home-based exercise programmes found to be as effective as supervised exercise programmes \[[@R103],[@R104]\].

The fundamental role of the case manager (typically an experienced nurse with relevant post-graduate qualifications and excellent communication skills), is coordination and navigation, marshalling both personnel and resources needed to carry out required patient care activities \[[@R105]\]; this includes involving families and caregivers. The case manager is responsible for exchanging information among the various providers to help ensure that the patient's needs and preferences for health services and information are met \[[@R106]\]. Given the complexity and potential for competing priorities in this clinical setting, it is critical that the need for all therapies, especially those with risk for harm, be critically assessed. For example, polypharmacy is ubiquitous in this patient population and a process of "de-prescribing" should be considered. This may include weaning central nervous system-active medicines (benzodiazepines, opioids), corticosteroids, and even cardiovascular drugs (e.g. statins, beta-blockers) over a timeframe of weeks to months \[[@R107],[@R108]\].

4.5. Step 5: Evaluate health outcomes well beyond acute hospitalisation and encompass all-cause events and a person-centred perspective in affected individuals {#S18}
---------------------------------------------------------------------------------------------------------------------------------------------------------------

Despite an understandable focus on immediate and costly rebounds to hospital in the short-term (i.e. within 30-days) \[[@R109]--[@R112]\], there is a strong rationale for adopting a longer and more holistic perspective to reflect the entire patient journey. The classical description of the natural history of HF reinforces this point; periods of clinical instability are typically interspersed with periods of relative stability \[[@R113]\]. Clinical studies of disease management programmes often adopt singular endpoints (e.g. risk of re-hospitalisation) over a short period of time and/or confine analyses to those events relating to the syndrome (i.e., HF specific). However, such an approach is limited from both a patient and health service perspective because there is clear potential for longer survival free from all-cause hospitalisation and with improved HRQoL. In simple terms, restricting follow-up to a short-time period (e.g. 30-days to 3-months) belies the complex interplay between short-term and long-term stability with respect to the potential benefit of more intensive management. For example, a "therapeutic" early readmission may result in fewer hospital days and better quality of life over the ensuing 12-month period.

These considerations do not undermine the importance of monitoring short-term outcomes; particularly when one considers that 20--25% of HF patients are readmitted within 30-days of hospital discharge \[[@R13]\]. Due to the costs of hospitalisation \[[@R10]\], scrutiny of readmissions has intensified in many countries. In this regard, multimorbidity has been identified as playing a critical role in driving both early and late readmissions in HF \[[@R18]\]. Indeed, two-thirds of patients readmitted within 30-days are hospitalised for a condition other than HF \[[@R13]\]. On this basis, there is a strong rationale to examine the overall pattern of morbidity and mortality (i.e. on an all-cause basis) over the longer-term; particularly when considering the pattern of multimorbidity present (derived from systematic profiling). Concurrently, the desire to involve patients in setting their own goals provides a strong argument for evaluating the relative success of management from a person-centred perspective, such as patient-reported HRQoL and satisfaction with health service delivery.

[Fig. 2](#F2){ref-type="fig"}: Pragmatic interpretation of how the 5 key recommendations for improving health outcomes in HF and multimorbidity might be applied on a differential basis, illustrates how the five steps outlined above might be applied to improve health outcomes in this increasingly common patient cohort; as suggested by this figure, patients with HF and multimorbidity now represent the majority of those hospitalised with HF. However, future research is required to determine how to apply these steps in a cost-efficient manner (including the use of information technology to facilitate profiling and communication strategies) and, to determine if the steps do indeed achieve better health outcomes in a range of health care settings.

5. Discussion {#S19}
=============

There is overwhelming evidence that multimorbidity in HF is a growing problem within an ageing population of HF patients. For example, according to U.S. Census Bureau projections, between 2000 and 2030, those 65 years and over are expected to increase from 34.8 million to over 70.3 million. In addition, those aged ≥85 years are the fastest growing age group, and the number of 85+ year olds in the US is expected to increase fivefold by 2050 \[[@R114]\]. Since approximately 75% of older Americans have two or more chronic conditions, the number of patients with HF and multimorbidity will inevitably continue to rise \[[@R115]\]. Not only is multimorbidity becoming more common, it is associated with poor health outcomes that potentially defy disease management strategies developed for younger and less complex cases of HF. As such, without pro-active management strategies to stabilise the clinical status of affected individuals in the longer-term, progression to geriatric syndromes such as falls, worsening renal function, and repetitive hospitalisations that ultimately lead to disability, frailty, loss of independence, and death will continue to occur with accelerating frequency \[[@R114],[@R115]\].

The potential for an increasing pool of patients with HF and multimorbidity to generate an unsustainable wave of patients with complex health care needs that are currently poorly served by existing health systems cannot be over-stated. As previously suggested by our group \[[@R15]\], reducing hospitalisations for any particular problem (e.g. acute decompensated HF) has the potential for avoiding deleterious consequences of hospitalisation itself, including delirium, iatrogenic illness, infections, deconditioning, sarcopenia, and increased falls risk. Recognising and addressing these risks and potential adverse effects is critical for reducing disability and optimising long-term health outcomes. For example, sarcopenia represents an increasingly important health problem in older adults \[[@R116]\]. For the HF patient, an initial hospital admission with associated bed-rest is likely to exacerbate underlying muscle dysfunction and wasting \[[@R117]\]; increasing the risk of recurrent hospitalisation in the absence of proactive mobilisation and occupational therapy \[[@R118],[@R119]\]. Similarly, catastrophic fall risk increases exponentially in the hospital setting; something that is routinely observed in the clinical management of older patients with HF and multimorbidity. Therefore, more pro-active efforts to minimise age-related physical decline and dysfunction are necessary \[[@R120]\].

In writing this position paper, we explicitly acknowledge the inherent limitations of our review of the literature relating to HF and multimorbidity in respect to a predominant focus on co-morbidity as opposed to multimorbid interactions (the latter reflecting the limitations of the literature in this regard). The prevalence and influence of specific conditions (including the ten conditions of specific interest) will undoubtedly vary within different HF populations. We have made no distinction between HF with reduced or preserved ejection fraction. At the same time, we have not focused on the most common antecedents of HF (hypertension and ischaemic heart disease) as we believe these are routinely addressed in the majority of patients with HF. This paper is not a guideline or a systematic review. However, we have intentionally focussed on providing a framework of clinical actions rather than specific recommendations for clinical management; as emphasised repeatedly, management needs to be individualised while considering the type of information provided in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.

As emphasised throughout this position paper, any approach to the complex issues engendered by an increasing number of individuals with HF and multimorbidity requires an overarching, strategic approach. Our clinical framework for action, comprising the five key steps of ARISE-HF, can be best viewed through the prism of a previously published policy framework (and overarching goals) for improving health outcomes and HRQoL in individuals with multimorbidity \[[@R121]--[@R123]\]: Foster health care and public health system changes to improve the health of with HF and multimorbidity. This includes developing evidence-supported models to improve care coordination, defining appropriate health care outcomes and providing incentives to make positive changes to the health care system.Facilitate self-care, wherever possible, with an equal emphasis on facilitating home and community-based services.Provide better tools, strategies and information to health professionals directly managing individuals with multimorbidity so they can improve the effectiveness of care delivery and subsequent health out-comes.Undertake health services research to fill critical gaps in our understanding of multimorbidity in HF with an emphasis on clinical, community, and patient-centred studies that seek to develop cost-effective models of care.

In the future, we anticipate a greater focus on managing multimorbidity in HF in clinical practice guidelines but with a far greater emphasis on principles of individualised management rather than specific instructions. We emphasise, therefore, that this clinical framework, generated from a diverse collection of health professionals with practical expertise in the management of patients with multimorbidity, complements existing HF guidelines \[[@R124],[@R125]\]. Our future challenge is to determine how best to incorporate what we have proposed into clinical practice and to demonstrate that it does indeed, as we expect, improve health outcomes in this growing patient population.
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###### 

Search terms used to identify published reports focussing on HF and the ten pre-specified concurrent conditions with total citations found.

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Comorbidity                  Search terms                                                                                         Citations
  ---------------------------- ---------------------------------------------------------------------------------------------------- -----------
  Anaemia                      Anaemia OR anemia\                                                                                   303
                               AND heart failure\                                                                                   
                               AND Management OR treatment                                                                          

  Sleep disordered breathing   Sleep disordered breathing OR obstructive sleep apnoea OR central sleep apnoea\                      179
                               AND heart failure\                                                                                   
                               AND management OR treatment                                                                          

  Respiratory disease          Respiratory disease OR dyspnoea OR chronic obstructive pulmonary disease\                            817
                               AND heart failure\                                                                                   
                               AND management OR treatment                                                                          

  Diabetes mellitus            Diabetes mellitus\                                                                                   486
                               AND heart failure\                                                                                   
                               AND management OR treatment                                                                          

  Depression                   Depression\                                                                                          387
                               AND heart failure\                                                                                   
                               AND management OR treatment                                                                          

  Renal impairment             Renal impairment OR renal dysfunction\                                                               322
                               AND heart failure\                                                                                   
                               AND management OR treatment                                                                          

  Cognitive impairment         Cognitive impairment\                                                                                74
                               AND heart failur\                                                                                    
                               AND management OR treatment                                                                          

  Musculoskeletal disorders    Musculoskeletal disorders OR osteoporosis OR osteopenia OR osteoarthritis OR rheumatoid arthritis\   105
                               AND heart failure\                                                                                   
                               AND management OR treatment                                                                          

  Arrhythmias                  Arrhythmias OR atrial fibrillation\                                                                  814
                               AND heart failure\                                                                                   
                               AND management OR treatment                                                                          

  Thyroid disease              Thyroid disease OR hyperthyroidism OR hypothyroidism\                                                86
                               AND heart failure\                                                                                   
                               AND management OR treatment                                                                          
  ---------------------------------------------------------------------------------------------------------------------------------------------

###### 

Suggested framework for documenting and quantifying multimorbidity in HF.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Co-morbidity                         Data source and determination                                                                                                                                                                                                               Definition/deficit threshold
  ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Anaemia                              Full blood examination during hospital admission                                                                                                                                                                                            Serum Hb level b 130 (women)/b120 g/L (men) \[[@R126],[@R127]\]

  Atrial and ventricular arrhythmias   Review of medical notes plus review of prescribed pharmacotherapy at discharge\                                                                                                                                                             Confirmation of AF, other atrial arrhythmias, 2nd or 3rd degree heart block, VT/VF with prescription of anti-arrhythmic therapy or pacemaker/defibrillator device \[[@R128]\]
                                       If high clinical suspicion of undiagnosed arrhythmia - 12-lead ECG, inpatient telemetry or extended ECG Holter monitoring                                                                                                                   

  Cognitive impairment/dementia        Assessed via Montreal Cognitive Assessment (MoCA) tool prior to hospital discharge by trained personnel                                                                                                                                     Documented diagnosis of dementia or MoCA score b 26 out of a maximal possible score of 30 \[[@R129]\]

  Depression/anxiety                   Assessed via PQ-2 \[[@R130]\] questionnaire prior to hospital discharge by trained personnel plus review of medical notes and prescribed pharmacotherapy at discharge. If positive, apply more comprehensive tool (e.g. HADS) \[[@R131]\]   Positive response to depressive symptoms and/or confirmed diagnosis (with active anti-depressant/anxiolytic) of depression or anxiety

  Diabetes and metabolic disorders     Review of medical notes and prescribed pharmacotherapy at discharge\                                                                                                                                                                        Documented diagnosis of Type 2 Diabetes or obesity BMI N 30 kg/m^2^ plus dyslipidaemia and/or hypertension (metabolic syndrome)
                                       Calculation of body mass index (BMI)\                                                                                                                                                                                                       
                                       If high clinical suspicion of underlying diabetes HbA1c and/or glucose tolerance tests                                                                                                                                                      

  Musculoskeletal disorders            Review of medical notes and prescribed pharmacotherapy at discharge\                                                                                                                                                                        Documented diagnosis of arthritis, osteoporosis, gout or any other musculoskeletal condition requiring active therapy (e.g. anti-inflammatory or analgesia)
                                       Frailty test with hand-grip manometer, gait speed, six-minute walk test, and Short Physical Performance Battery including static balance, gait speed and getting in and out of a chair \[[@R101]\]                                          

  Renal impairment                     Electrolytes and renal function obtained during hospital admission Calculation of body mass index                                                                                                                                           Estimated glomerular filtration rate b 60 mL/min/1.73 m^2^ \[[@R132]\]

  Respiratory disease                  Review of medical notes and prescribed pharmacotherapy at discharge\                                                                                                                                                                        Lung function confirmation of COPD, asthma and/or other chronic pulmonary condition requiring active treatment \[[@R133]\]
                                       If high clinical suspicion of underlying respiratory disease - formal lung function tests                                                                                                                                                   

  Thyroid disease                      Review of medical notes and prescribed pharmacotherapy at discharge\                                                                                                                                                                        Documented hyper/ hypothyroidism based on according to national standards with associated anti-thyroid or thyroxine replacement therapy \[[@R134]\]
                                       If high clinical suspicion of, or historical lack of screening, perform thyroid function tests (including thyroid stimulating hormone levels) at hospital admission                                                                         

  Sleep disorders                      Review of medical notes and prescribed sleep support device. If high clinical suspicion of sleep disordered breathing perform formal sleep studies\                                                                                         Documented diagnosis of obstructive or central sleep disordered breathing
                                       Use of a screening questionnaire in hospital to identify those with sleep-disordered breathing (135)                                                                                                                                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
